These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 3092937)

  • 1. Sulphinpyrazone and the platelet serotoninergic mechanism in ischaemic heart disease.
    Puri VK; Rawat A; Sharma A; Mehrotra A; Hasan M; Shanker K; Verma M; Sinha JN; Bhargava KP
    Br Med J (Clin Res Ed); 1986 Sep; 293(6547):591-3. PubMed ID: 3092937
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A serial study of platelet reactivity throughout the first six months after myocardial infarction: its modification by sulphinpyrazone.
    Kubik MM; Richardson SG
    Postgrad Med J; 1987 May; 63(739):351-6. PubMed ID: 3118351
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transcoronary platelet thromboxane A2 formation without platelet trapping in patients with coronary stenosis-effect of sulphinpyrazone treatment.
    Cortellaro M; Boschetti C; Antoniazzi V; Moreo G; Repetto S; Verna E; Boscarini M; Limido A; Binaghi G; Polli EE
    Thromb Haemost; 1983 Dec; 50(4):857-9. PubMed ID: 6665767
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Failure of sulphinpyrazone to affect platelet survival in patients with rheumatic heart valvular disease: a double blind study using 75Se-methionine labeled platelets.
    Fabris F; Casonato A; Randi ML; Schivazappa L; Schiavinato L; Girolami A
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1983; 110(4):594-601. PubMed ID: 6196274
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sulphinpyrazone in acute myocardial infarction: studies on cardiac rhythm and renal function.
    Wilcox RG; Richardson D; Hampton JR; Mitchell JR; Banks DC
    Br Med J; 1980 Aug; 281(6239):531-4. PubMed ID: 7000264
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sulphinpyrazone in post-myocardial infarction. Report from the Anturan Reinfarction Italian Study.
    Lancet; 1982 Jan; 1(8266):237-42. PubMed ID: 6120272
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Haemostatic function changes in a trial on the secondary prevention of myocardial infarction with sulphinpyrazone.
    Cortellaro M; Boschetti C; Fassio G; Baroni L; Polli EE
    Acta Haematol; 1981; 65(3):193-204. PubMed ID: 6785974
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Platelet function in coronary artery disease: effects of coronary surgery and sulfinpyrazone.
    Cade JF; Doyle DJ; Chesterman CN; Morgan FJ; Rennie GC
    Circulation; 1982 Jul; 66(1):29-32. PubMed ID: 6211296
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Platelet serotonergic mechanisms in ischaemic heart disease.
    Puri VK; Verma M; Saxena AK; Shanker K
    Thromb Res; 1990 Feb; 57(3):445-51. PubMed ID: 2315895
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aspirin and other platelet-aggregation inhibiting drugs.
    Gallus AS
    Med J Aust; 1985 Jan; 142(1):41-7. PubMed ID: 3880861
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Decrease in renal function due to sulphinpyrazone treatment early after myocardial infarction.
    Lijnen P; Boelaert J; van Eeghem P; Daneels R; Schurgers M; de Jaegere P; van der Stichele E; Vincke J; Fagard R; Verschueren LJ; Amery A
    Clin Nephrol; 1983 Mar; 19(3):143-6. PubMed ID: 6340878
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A controlled study of the effect of sulfinpyrazone on platelet survival and on platelet-bound 14C-serotonin release in patients with previous myocardial infarction.
    Cortellaro M; Boschetti C; Fassio G; Basagni M; Polli EE
    Acta Haematol; 1979; 61(2):68-74. PubMed ID: 217218
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A critical appraisal of the clinical efficiency of anti-platelet drugs.
    Lecompte T; Samama M
    Agents Actions Suppl; 1986; 20():203-14. PubMed ID: 3544741
    [No Abstract]   [Full Text] [Related]  

  • 14. Controlled ex-vivo effect of sulfinpyrazone on platelet function of myocardial infarction patients.
    Cortellaro M; Fassio G; Boschetti C; Basagni M; Polli EE
    Haematologica; 1979 Apr; 64(2):173-89. PubMed ID: 112008
    [No Abstract]   [Full Text] [Related]  

  • 15. Platelet serotonin uptake during myocardial ischemia.
    Oei HH; Hughes WE; Schaffer SW; Longenecker GL; Glenn TM
    Am Heart J; 1983 Nov; 106(5 Pt 1):1077-81. PubMed ID: 6356847
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Factors influencing platelet serotonin uptake in essential hypertension.
    Jafri SM; Chandra N; Dhawan S; Soni D; Chandra M; Shanker K
    Int J Cardiol; 1992 Mar; 34(3):327-33. PubMed ID: 1563858
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Physostigmine effects on serotonin uptake in human blood platelets.
    Rausch JL; Janowsky DS; Risch SC; Huey LY
    Eur J Pharmacol; 1985 Feb; 109(1):91-6. PubMed ID: 3996470
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sulphinpyrazone and renal function following myocardial infarction.
    Choudhury SL; Taylor SH; Wieringa G; Swaminathan R; Morgan DB
    Eur J Clin Pharmacol; 1983; 24(6):747-50. PubMed ID: 6884411
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Platelet serotonin uptake in duodenal ulcer patients.
    Misra R; Komandur R; Chandra M; Shankar K; Zaheer SM; Ram S; Gujrati VR
    Indian J Gastroenterol; 1994 Apr; 13(2):54-5. PubMed ID: 8206537
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antithrombotic effects of drugs which suppress platelet function: their potential in prevention growth of tumour cells.
    Turpie AG
    Prog Clin Biol Res; 1982; 89():31-62. PubMed ID: 7051035
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.